This document describes a process for the high purity and high concentration recovery of monovalent products via continuous ion exchange from aqueous solution for further down-stream purification.

This document describes a process for the high purity and high concentration recovery of monovalent products via continuous ion exchange from aqueous solution for further down-stream purification.

This document describes a process for the high purity and high concentration recovery of monovalent products via continuous ion exchange from aqueous solution for further down-stream purification.

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G.sup.1, G.sup.1′, G.sup.2, G.sup.2′, G.sup.3, L.sup.1, L.sup.1′, L.sup.2, L.sup.2′, X, X′, Y and Y′ are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, Y, L.sup.1, L.sup.2, L.sup.3, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, Y, L.sup.1, L.sup.2, L.sup.3, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##

Methods are provided for synthesizing high purity niobium or rhenium powders by a combustion reaction. The methods can include: forming a combustion synthesis solution by dissolving in water an oxidizer, a fuel, and at least one base-soluble, ammonium salt of niobium or rhenium in amounts that yield a stoichiometric burn when combusted; and heating the combustion synthesis solution to a temperature sufficient to substantially remove the water and to initiate a self-sustaining combustion reaction.

The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril, inter alia via nitro 5 compounds. It further relates to new intermediate compounds and their use for said new chemical synthesis route, as well as a new catalyst ligand.

The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril, inter alia via nitro 5 compounds. It further relates to new intermediate compounds and their use for said new chemical synthesis route, as well as a new catalyst ligand.

The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas:

##STR00001##

wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.